Investors Home



Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also developing Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.

Stock Snapshot
NASDAQGLMD
Corporate Presentation
NASDAQGLMD
Loading...
Display Events
 
 
 
 
Chart Style